A subsidiary of Sun Pharma has reached an agreement to buy the assets of Canada's Antibe Therapeutics, a developer of drugs ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...

Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...

Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorders of the ...

At the top of that list, unsurprisingly, are Novo Nordisk obesity drugs Ozempic, Rybelsus, and Wegovy, all grouped together ...

While this subjective cognitive decline (SCD) linked to menopause tends to be transient, it can often occur at an age when ...

Generative artificial intelligence (GenAI) player Bioptimus has swelled its coffers with another financing round, raising $41 ...

As a result of the disappointing results, Boehringer said that it was abandoning a long-term extension trial called CONNEX-X, ...

The establishment of the ERAS protocols catalyses the changes in the IV treatment settings and highlights the need for a ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...

The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a ...